A Novel Anti-cancer Agent, SJ-8029, Inhibits Angiogenesis and Induces Apoptosis

  • Yi Eui-Yeun (Department of Molecular Biology, Pusan National University) ;
  • Jeong Eun-Joo (Department of Molecular Biology, Pusan National University) ;
  • Song Hyun-Seok (Department of Molecular Biology, Pusan National University) ;
  • Kang Dong-Wook (Central Research Institute, Samjin Pharm. Co., Ltd.) ;
  • Joo Jeong-Ho (Central Research Institute, Samjin Pharm. Co., Ltd.) ;
  • Kwon Ho-Seok (Central Research Institute, Samjin Pharm. Co., Ltd.) ;
  • Lee Sun-Hwan (Central Research Institute, Samjin Pharm. Co., Ltd.) ;
  • Park Si-Kyung (Central Research Institute, Samjin Pharm. Co., Ltd.) ;
  • Chung Sun-Gan (Central Research Institute, Samjin Pharm. Co., Ltd.) ;
  • Cho Eui-Hwan (Central Research Institute, Samjin Pharm. Co., Ltd.) ;
  • Kim Yung-Jin (Department of Molecular Biology, Pusan National University)
  • Published : 2006.09.01

Abstract

A new piperazine derivative, 8J-8029, is a synthetic anti-cancer agent which exhibits both microtubule and topoisomerase II inhibiting activities. In this study, we investigated the ability of 8J-8029 for anti-angiogenesis and apoptosis. 8J-8029 decreased the bFGF-induced angiogenesis in the CAM and the mouse Matrigel implants, in vivo. 8J-8029 inhibited the proliferation, migration, invasion, tube fonnation, and expression of MMP-2 in BAECs. In addition, 8J-8029 reduced the cell viability in HepG2 cells, caused the production of fragmented DNA and the morphological changes corresponding to apoptosis. 8J-8029 also elicited the release of cytochrome c and the activation of caspase-3. Taken together, these results suggest 8J-8029 may be a candidate for anti-cancer agent with the ability to inhibit the angiogenesis of endothelial cells and to induce the apoptosis of tumor cells.

Keywords